Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 February 2021 The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.
14 December 2020 Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.
19 June 2019 Pharmaceutical companies Merck & Co, Eli Lilly, and Amgen are suing the US Department of Health and Human Services over proposed rules which would force companies to disclose the list prices of drugs in TV advertisements.
